ArticleNano letters2025
Probing the Role of Lipid Nanoparticle Elasticity on mRNA Delivery to the Placenta.
Article in Nano letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Preparation of targeted lipid nanoparticles for precision nucleic acid delivery.Nature protocols · 2026Review
- Preparation of placenta-tropic mRNA lipid nanoparticles for pregnancy disorders.Nature protocols · 2026Review
- Enhancing Lipid Nanoparticle-Mediated Circular RNA and mRNA Expression in the Placenta through Inhibition of IFNAR-JAK-STAT Signaling.Nano letters · 2026Article
- Mechanical insights into regulation of bio-nano interactions for lipid-based nanocarriers.Discover nano · 2026Review
- The RNA delivery dilemma-lipid versus polymer nanoparticle platforms.Drug delivery and translational research · 2026Article
- A rapid and reliable strategy for identification of LNP and protein corona in vitro and in vivo.International journal of pharmaceutics: X · 2026Article
- Tissue-specific gene delivery approaches.Bioengineering & translational medicine · 2026Review
- CORE: Cholesterol Altered Lipid Nanoparticles for Splenic Expression of mRNA Payloads.Advanced healthcare materials · 2026Article
- Innovative γ-Oryzanol and KC2 Based Lipid Nanoparticles: OryKL Platform Provides Safe and Efficient In Vivo mRNA Delivery.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Spatiotemporal targeting of messenger RNA lipid nanoparticles to the endometrium for the treatment of reproductive disorders.Nature nanotechnology · 2026Article
- Examining the effect of lipid nanoparticle elasticity on endocytosis and mRNA delivery to cancer cells.Med-X · 2026Article
- Nanotechnology strategies for endometrium health: Are we on the right track?Bioactive materials · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
It is well established that the physicochemical properties of lipid nanoparticles (LNPs) can govern their interactions with various biological barriers. One property hypothesized to influence nanoparticle-cell interactions is elasticity. Here, we formulate LNPs with naturally occurring cholesterol analogs to tune LNP elasticity and study its role on mRNA delivery to the placenta. LNP elasticity was measured via atomic force microscopy where these LNPs exhibited Young's moduli ranging from 71.0 ± 26.2 to 411.4 ± 145.7 kPa. In vitro screening of these LNPs in placental trophoblasts showed that stiffer LNPs improved LNP uptake and mRNA delivery compared with softer LNPs. Following intravenous administration to pregnant mice, the stiffer LNPs incorporating β-sitosterol enhanced placental and reduced liver mRNA delivery compared with softer LNPs containing only cholesterol. These results demonstrate the ability of stiffer LNPs to promote placental mRNA delivery and highlight the potential of tuning LNP elasticity to improve LNP-mediated mRNA delivery to organs of interest.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.